Magdalena Mazurkiewicz
Overview
Explore the profile of Magdalena Mazurkiewicz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
323
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Golec de Zavala A, Keenan O, Ziegler M, Mazurkiewicz M, Nalberczak-Skora M, Ciesielski P, et al.
Psychol Sci
. 2024 Jan;
35(2):137-149.
PMID: 38232344
This research tested the hypothesis that mindful-gratitude practice attenuates the robust association between collective narcissism and prejudice. In Study 1 (a between-subjects study using a nationally representative sample of 569...
2.
Golec de Zavala A, Forster C, Ziegler M, Nalberczak-Skora M, Ciesielski P, Mazurkiewicz M
Appl Psychol Health Well Being
. 2024 Jan;
16(3):1122-1140.
PMID: 38183357
Understanding of the exact trajectories of mood improvements during mindfulness practice helps to optimize mindfulness-based interventions. The Mindfulness-to-Meaning model expects mood improvements to be linear, incremental, and cumulative. Our findings...
3.
Golec de Zavala A, Keenan O, Ziegler M, Ciesielski P, Wahl J, Mazurkiewicz M
Appl Psychol Health Well Being
. 2023 Jul;
16(1):42-59.
PMID: 37432062
A randomized-controlled-trial study (N = 219) tested two pre-registered hypotheses that mobile-phone app-based mindfulness training improves wellbeing and increases self-transcendent emotions: gratitude, self-compassion, and awe. Latent change score modeling with...
4.
Hase A, Behnke M, Mazurkiewicz M, Wieteska K, Golec de Zavala A
Psychophysiology
. 2021 Jun;
58(9):e13879.
PMID: 34128555
The negative consequences of personal exclusion have been demonstrated by multiple studies. Less is known about the consequences of witnessing one's own group being excluded by other groups, although studies...
5.
Hillert E, Brnjic S, Zhang X, Mazurkiewicz M, Saei A, Mofers A, et al.
Cancer Lett
. 2019 Feb;
448:70-83.
PMID: 30768956
Proteasome inhibitors have been shown to induce cell death in cancer cells by triggering an acute proteotoxic stress response characterized by accumulation of poly-ubiquitinated proteins, ER stress and the production...
6.
Pellegrini P, Serviss J, Lundback T, Bancaro N, Mazurkiewicz M, Kolosenko I, et al.
Cancer Cell Int
. 2018 Sep;
18:147.
PMID: 30263014
Background: Drug screening for the identification of compounds with anticancer activity is commonly performed using cell lines cultured under normal oxygen pressure and physiological pH. However, solid tumors are characterized...
7.
Zhang X, Pellegrini P, Saei A, Hillert E, Mazurkiewicz M, Olofsson M, et al.
Biochem Pharmacol
. 2018 Aug;
156:291-301.
PMID: 30149015
Human cancers are characterized by intrinsic or acquired resistance to apoptosis and evasion of apoptosis has been proposed to contribute to treatment resistance. Bis-benzylidine piperidone compounds, containing α,β-unsaturated carbonyl functionalities,...
8.
Mazurkiewicz M, Hillert E, Wang X, Pellegrini P, Olofsson M, Selvaraju K, et al.
Oncotarget
. 2017 Apr;
8(13):21115-21127.
PMID: 28423502
The non-genotoxic nature of proteasome inhibition makes it an attractive therapeutic option for the treatment of pediatric malignancies. We recently described the small molecule VLX1570 as an inhibitor of proteasome...
9.
Wang X, Mazurkiewicz M, Hillert E, Olofsson M, Pierrou S, Hillertz P, et al.
Sci Rep
. 2016 Jul;
6:30667.
PMID: 27472448
No abstract available.
10.
Wang X, Mazurkiewicz M, Hillert E, Olofsson M, Pierrou S, Hillertz P, et al.
Sci Rep
. 2016 Jun;
6:26979.
PMID: 27264969
Inhibition of deubiquitinase (DUB) activity is a promising strategy for cancer therapy. VLX1570 is an inhibitor of proteasome DUB activity currently in clinical trials for relapsed multiple myeloma. Here we...